Cardiff Oncology, Inc. (CRDF) a clinical-stage biotechnology company developing therapies targeting PLK1 inhibition, announced financial results for the full year ended December 31, 2025, and provided a business update highlighting progress in its lead program, Onvansertib, for RAS-mutated metastatic colorectal cancer (mCRC).
Full Year 2025 Results
Royalty revenues were $0.6 million, compared to $0.7 million in 2024.Total operating expenses were $49.6 million, essentially flat versus $49.3 million in 2024.
Net loss was $45.9 million, or $0.69 per share, compared to a net loss of $45.5 million, or $0.95 per share, in 2024.
Cash, cash equivalents and short-term investments totaled $58.3 million at year. The company expects this cash position to fund operations into the first quarter of 2027.
Business Update
•Cardiff reported positive data from the randomized Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC. The 30 mg Onvansertib+ FOLFIRI/bev arm achieved an objective response rate of 72.2%, compared to 43.2% across combined standard-of-care arms.
•Progression-free survival also improved significantly, with no added toxicity observed.
•Based on these results, Cardiff plans to advance the 30 mg dose of Onvansertib with FOLFIRI/bev into a registrational program, with detailed data and regulatory plans expected in the first half of 2026.
•Additional investigator-sponsored data in chronic myelomonocytic leukaemia (CMML) presented at ASH 2025 showed preliminary efficacy in approximately 40% of patients.
Leadership Update
In January 2026, Cardiff announced executive changes to support late-stage development. Mani Mohindru, PhD was appointed interim Chief Executive Officer, while Brigitte Lindsay was promoted to Chief Accounting Officer. The company has initiated a search for a permanent CEO and CFO.
CRDF has traded between $1.48 and $4.86 over the past year. The stock closed Tuesday's session at $1.70, up 8.97%.
For comments and feedback contact: editorial@rttnews.com
Business News
May 08, 2026 15:50 ET Manufacturing and services sector survey results and labor market data from main economies were the highlight on the economics news front this week. Factory orders and jobs report dominated the news flow in the U.S. Similarly, industrial production data from German garnered attention in Europe. In Asia, purchasing managers’ survey results from China and the central bank decision from Australia were in focus.